MaaT Pharma Presents Positive 18-month Data for MaaT013

• Positive efficacy and safety results in 140 patients treated with MaaT013 in acute graftversus-host disease (aGvHD) as part of the MaaT Pharma Early Access Program (EAP).
• Gastrointestinal overall response rate (GI-ORR) of 52% observed at Day (D) 28.
• Long-term survival data at 18 months with 42% overall survival (OS) in all patients and 58% in responder patients to MaaT013.
• Used in 3rd line, MaaT013 exhibits a high and durable response rate (with 63% GI-ORR at D28 and 53% at D56), translating to the highest overall survival in this population of patients when compared to reported evidence in the literature (Abedin et al., 2021).
• A pivotal Phase 3 trial evaluating MaaT013 (ARES trial – NCT04769895; n=75) in patients with corticosteroid and ruxolitinib-refractory GI-aGvHD is currently ongoing with primary endpoint expected in mid Q4-2024.

Lyon, France, April 15th, 2024 – 7.30 am CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, presents a summary of its oral presentation at the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) currently being hosted in Glasgow, Scotland from 14-17 April 2024. The presentation is scheduled for April 17th by Dr. Malard, Professor of Hematology at Saint-Antoine Hospital and Sorbonne University in Paris and is based on the abstract made available on the website of the event.

Read the press release